Higher CSF Orexin-A Links to Worse Cognition in Alzheimer's Disease, Inversely Correlating with NREM Sleep Oscillations
Background
Sleep-wake dysregulation and elevated cerebrospinal fluid (CSF) orexin concentrations are increasingly implicated in Alzheimer disease (AD) pathology. NREM sleep spindles (SPs) and slow oscillations (SOs) are critical for memory consolidation and are known to be affected in neurodegenerative conditions. However, the precise relationship between these specific NREM oscillatory activities and CSF orexin levels in symptomatic AD patients, and how they might influence cognitive decline and biomarker associations, has remained largely uncharacterized. Understanding this link could reveal novel therapeutic targets for AD.
Study Design
This prospective observational cohort study enrolled 60 participants (mean age 74.7 years, 30 women) with biomarker-confirmed mild-to-moderate Alzheimer disease from a tertiary memory clinic. Each participant underwent overnight polysomnography (PSG) and morning CSF sampling. SP and SO activity were quantified using validated automated algorithms. CSF was assayed for orexin-A, amyloid-β42 (Aβ42), phosphorylated tau181 (pTau181), total tau, and YKL-40. Cognitive performance (ADAS-Cog, MMSE) and neuropsychiatric symptoms (NPI) were assessed longitudinally over 36 months. Generalized linear models, adjusted for age, sex, Aβ42, and apnea-hypopnea index, were used to examine associations.
Results
Longer SO duration and higher SP density and power were significantly associated with lower CSF orexin concentrations. Specifically, SP density showed a strong inverse association (β = -187.37 pg/mL, 95% CI -344.93 to -29.80). Notably, orexin was not associated with global sleep continuity metrics. Higher CSF orexin concentrations were significantly associated with worse global cognition, as measured by ADAS-Cog (β = 0.02, 95% CI 0.00-0.03). SO duration was found to moderate the association between orexin and ADAS-Cog (β = -0.001, 95% CI -0.002 to -0.000), while SP density moderated the association between orexin and NPI (β = -0.001, 95% CI -0.002 to -0.000). No direct associations were found between orexin and Aβ42 or pTau181 levels.
Higher CSF orexin-A concentrations were significantly associated with worse global cognition (ADAS-Cog: β = 0.02, 95% CI 0.00-0.03), suggesting a direct link between orexin system hyperactivity and cognitive decline in Alzheimer disease.
Key Findings
- Longer
SOduration and higherSPdensity/power associated with lower CSForexinlevels. SPdensity inversely correlated with CSForexin(β = -187.37 pg/mL, 95% CI -344.93 to -29.80).- Higher CSF
orexinconcentrations linked to worse global cognition (ADAS-Cog: β = 0.02, 95% CI 0.00-0.03). SOduration moderated theorexin-ADAS-Cogassociation (β = -0.001, 95% CI -0.002 to -0.000).SPdensity moderated theorexin-NPIassociation (β = -0.001, 95% CI -0.002 to -0.000).
Why It Matters
This study highlights that modulating the orexin system, potentially through interventions that enhance NREM sleep oscillations, could be a novel therapeutic strategy for Alzheimer disease. The findings reinforce the critical role of sleep architecture in neurodegeneration and cognitive function. For clinicians and biohackers, this suggests that optimizing sleep quality, particularly NREM sleep, might be a valuable adjunct in managing AD symptoms. While this observational study doesn't provide a direct protocol, it strengthens the rationale for clinical trials investigating orexin receptor antagonists (DORAs) in AD patients to improve sleep and potentially mitigate cognitive decline by targeting the orexin system and its impact on NREM sleep architecture.
alzheimer-disease
orexin
sleep
cognition
nrem-sleep
polysomnography